Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

2 treatments under study, led by Antipd1 Antibodypegasparaginasechidamide

Research Leaders

5 sponsors active, led by Severance Hospital

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 25/100

Termination Rate

0.0%

0 terminated out of 2 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

100%

1 of 1 completed with results

Key Signals

1 with results100% success

Data Visualizations

Phase Distribution

2Total
Phase 2 (2)

Trial Status

Unknown1
Completed1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (2)

Showing 2 of 2 trials
NCT04414969Phase 2Unknown

Anti-PD-1 Antibody Combined With Peg-Asparaginase and Chidamide for the Early Stage of NK/T Cell Lymphoma

NCT01007526Phase 2CompletedPrimary

Concomitant Chemo-radiotherapy Plus VIDL Chemotherapy in NK/T-cell Lymphoma

Showing all 2 trials

Research Network

Common Treatments

  • Antipd1 Antibodypegasparaginasechidamide1
  • Ccrt Followed By Vidl Chemotherapy1

Active Sponsors

  • Severance Hospital1
  • National Cancer Center, Korea1
  • Hunan Cancer Hospital1
  • Asan Medical Center1
  • Samsung Medical Center1

Top Investigators

Related Conditions

  • Epigenetic Disorder1
  • Immune Checkpoint Inhibitor1
  • Chemotherapy Effect1

Activity Timeline